DSLT for Reducing Medication in Glaucoma

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma. The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT. Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.

NCT Number	NCT07390890
Lead Sponsor	The Eye Institute of West Florida Collaborators: Sengi
Conditions	Primary Open Angle Glaucoma, Ocular Hypertension
Enrollment	60 participants
Start Date	2026-02-10
Primary Completion	2027-01-26 (estimated)
Study Completion	2027-01-26 (estimated)
Updated on ClinicalTrials.gov	2026-04-20